Pmv Capital Surpluse vs Accounts Payable Analysis

PMVP Stock

USD 1.82 0.03 1.68%

Pmv PharmaceuticalsI financial indicator trend analysis is much more than just breaking down Pmv PharmaceuticalsInc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pmv PharmaceuticalsInc is a good investment. Please check the relationship between Pmv PharmaceuticalsI Capital Surpluse and its Accounts Payable accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pmv PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

Capital Surpluse vs Accounts Payable

Capital Surpluse vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pmv PharmaceuticalsInc Capital Surpluse account and Accounts Payable. At this time, the significance of the direction appears to have strong relationship.

The correlation between Pmv PharmaceuticalsI's Capital Surpluse and Accounts Payable is 0.65. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Pmv PharmaceuticalsInc, assuming nothing else is changed. The correlation between historical values of Pmv PharmaceuticalsI's Capital Surpluse and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Pmv PharmaceuticalsInc are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Capital Surpluse i.e., Pmv PharmaceuticalsI's Capital Surpluse and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.65

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Capital Surpluse

Accounts Payable

An accounting item on the balance sheet that represents Pmv PharmaceuticalsI obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Pmv PharmaceuticalsInc are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Pmv PharmaceuticalsI's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pmv PharmaceuticalsInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pmv PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

At this time, Pmv PharmaceuticalsI's Tax Provision is relatively stable compared to the past year. As of 06/02/2024, Issuance Of Capital Stock is likely to grow to about 52.1 M, while Selling General Administrative is likely to drop slightly above 17.1 M.

	2021	2022	2023	2024 (projected)
Interest Income	449K	3.6M	9.8M	10.3M
Net Interest Income	449K	3.6M	9.8M	10.3M

Interest Income Net Interest Income

Pmv PharmaceuticalsI fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other	Net Working Capital
Total Assets		0.87	0.85	0.99	0.81	0.98	0.67	-0.7	-0.74	0.75	0.76	0.66	0.44	-0.2	0.99	0.89	0.57	-0.91	0.92	0.79	-0.9	0.99	0.66	1.0	0.9	0.99
Other Current Liab	0.87		0.99	0.88	0.89	0.91	0.91	-0.37	-0.91	0.87	0.39	0.88	0.44	-0.38	0.82	0.88	0.89	-0.87	0.91	0.98	-0.85	0.88	0.88	0.82	0.94	0.81
Total Current Liabilities	0.85	0.99		0.85	0.92	0.88	0.92	-0.29	-0.92	0.92	0.36	0.89	0.46	-0.38	0.8	0.91	0.9	-0.83	0.91	0.98	-0.79	0.85	0.89	0.8	0.93	0.78
Total Stockholder Equity	0.99	0.88	0.85		0.78	1.0	0.69	-0.73	-0.74	0.7	0.75	0.66	0.45	-0.19	0.98	0.85	0.6	-0.95	0.93	0.81	-0.95	1.0	0.67	0.98	0.91	0.98
Other Liab	0.81	0.89	0.92	0.78		0.81	0.77	-0.23	-0.87	0.92	0.41	0.79	0.29	-0.5	0.77	0.96	0.74	-0.69	0.82	0.83	-0.64	0.78	0.78	0.77	0.87	0.76
Net Tangible Assets	0.98	0.91	0.88	1.0	0.81		0.72	-0.71	-0.77	0.71	0.72	0.69	0.41	-0.23	0.97	0.86	0.63	-0.95	0.93	0.83	-0.95	1.0	0.69	0.97	0.91	0.96
Property Plant And Equipment Net	0.67	0.91	0.92	0.69	0.77	0.72		-0.11	-0.9	0.83	0.1	0.85	0.65	-0.25	0.59	0.75	0.97	-0.74	0.87	0.97	-0.71	0.69	0.93	0.6	0.84	0.58
Net Debt	-0.7	-0.37	-0.29	-0.73	-0.23	-0.71	-0.11		0.14	-0.06	-0.9	-0.05	-0.13	-0.17	-0.74	-0.33	0.02	0.68	-0.51	-0.25	0.75	-0.73	-0.05	-0.74	-0.43	-0.75
Retained Earnings	-0.74	-0.91	-0.92	-0.74	-0.87	-0.77	-0.9	0.14		-0.84	-0.16	-0.96	-0.52	0.58	-0.68	-0.87	-0.86	0.8	-0.86	-0.91	0.73	-0.74	-0.98	-0.69	-0.95	-0.67
Accounts Payable	0.75	0.87	0.92	0.7	0.92	0.71	0.83	-0.06	-0.84		0.28	0.81	0.49	-0.32	0.7	0.93	0.81	-0.59	0.8	0.87	-0.53	0.7	0.82	0.7	0.81	0.68
Cash	0.76	0.39	0.36	0.75	0.41	0.72	0.1	-0.9	-0.16	0.28		0.03	0.13	0.2	0.82	0.52	-0.04	-0.56	0.55	0.26	-0.62	0.75	0.03	0.81	0.44	0.83
Non Current Assets Total	0.66	0.88	0.89	0.66	0.79	0.69	0.85	-0.05	-0.96	0.81	0.03		0.41	-0.65	0.59	0.78	0.88	-0.75	0.74	0.88	-0.66	0.66	0.97	0.6	0.89	0.58
Non Currrent Assets Other	0.44	0.44	0.46	0.45	0.29	0.41	0.65	-0.13	-0.52	0.49	0.13	0.41		0.28	0.42	0.46	0.5	-0.48	0.68	0.56	-0.45	0.45	0.61	0.43	0.53	0.42
Other Assets	-0.2	-0.38	-0.38	-0.19	-0.5	-0.23	-0.25	-0.17	0.58	-0.32	0.2	-0.65	0.28		-0.16	-0.38	-0.35	0.31	-0.15	-0.29	0.21	-0.19	-0.5	-0.16	-0.47	-0.15
Cash And Short Term Investments	0.99	0.82	0.8	0.98	0.77	0.97	0.59	-0.74	-0.68	0.7	0.82	0.59	0.42	-0.16		0.87	0.48	-0.88	0.89	0.73	-0.88	0.98	0.6	1.0	0.86	1.0
Common Stock Shares Outstanding	0.89	0.88	0.91	0.85	0.96	0.86	0.75	-0.33	-0.87	0.93	0.52	0.78	0.46	-0.38	0.87		0.68	-0.74	0.89	0.83	-0.69	0.85	0.79	0.87	0.91	0.86
Short Term Investments	0.57	0.89	0.9	0.6	0.74	0.63	0.97	0.02	-0.86	0.81	-0.04	0.88	0.5	-0.35	0.48	0.68		-0.66	0.75	0.95	-0.62	0.6	0.91	0.49	0.77	0.47
Non Current Liabilities Total	-0.91	-0.87	-0.83	-0.95	-0.69	-0.95	-0.74	0.68	0.8	-0.59	-0.56	-0.75	-0.48	0.31	-0.88	-0.74	-0.66		-0.9	-0.83	0.99	-0.95	-0.76	-0.89	-0.93	-0.88
Other Current Assets	0.92	0.91	0.91	0.93	0.82	0.93	0.87	-0.51	-0.86	0.8	0.55	0.74	0.68	-0.15	0.89	0.89	0.75	-0.9		0.9	-0.88	0.93	0.82	0.89	0.94	0.89
Other Stockholder Equity	0.79	0.98	0.98	0.81	0.83	0.83	0.97	-0.25	-0.91	0.87	0.26	0.88	0.56	-0.29	0.73	0.83	0.95	-0.83	0.9		-0.8	0.81	0.92	0.73	0.9	0.71
Total Liab	-0.9	-0.85	-0.79	-0.95	-0.64	-0.95	-0.71	0.75	0.73	-0.53	-0.62	-0.66	-0.45	0.21	-0.88	-0.69	-0.62	0.99	-0.88	-0.8		-0.95	-0.68	-0.88	-0.88	-0.88
Net Invested Capital	0.99	0.88	0.85	1.0	0.78	1.0	0.69	-0.73	-0.74	0.7	0.75	0.66	0.45	-0.19	0.98	0.85	0.6	-0.95	0.93	0.81	-0.95		0.67	0.98	0.91	0.98
Property Plant And Equipment Gross	0.66	0.88	0.89	0.67	0.78	0.69	0.93	-0.05	-0.98	0.82	0.03	0.97	0.61	-0.5	0.6	0.79	0.91	-0.76	0.82	0.92	-0.68	0.67		0.6	0.9	0.58
Total Current Assets	1.0	0.82	0.8	0.98	0.77	0.97	0.6	-0.74	-0.69	0.7	0.81	0.6	0.43	-0.16	1.0	0.87	0.49	-0.89	0.89	0.73	-0.88	0.98	0.6		0.87	1.0
Non Current Liabilities Other	0.9	0.94	0.93	0.91	0.87	0.91	0.84	-0.43	-0.95	0.81	0.44	0.89	0.53	-0.47	0.86	0.91	0.77	-0.93	0.94	0.9	-0.88	0.91	0.9	0.87		0.86
Net Working Capital	0.99	0.81	0.78	0.98	0.76	0.96	0.58	-0.75	-0.67	0.68	0.83	0.58	0.42	-0.15	1.0	0.86	0.47	-0.88	0.89	0.71	-0.88	0.98	0.58	1.0	0.86

Click cells to compare fundamentals

Pmv PharmaceuticalsI Account Relationship Matchups

Pmv PharmaceuticalsI fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	103.0M	365.5M	331.6M	270.3M	252.2M	254.1M
Other Current Liab	1.7M	4.8M	8.6M	7.3M	9.9M	6.2M
Total Current Liabilities	4.5M	6.4M	12.2M	10.8M	14.0M	9.2M
Total Stockholder Equity	(70.5M)	359.1M	308.6M	246.0M	225.7M	187.5M
Net Tangible Assets	(70.5M)	359.1M	308.6M	246.0M	282.9M	175.4M
Property Plant And Equipment Net	739K	569K	13.2M	20.5M	19.0M	10.1M
Net Debt	95.7M	(361.4M)	(161.3M)	(94.3M)	(25.2M)	(26.5M)
Retained Earnings	(75.4M)	(109.9M)	(167.7M)	(241.0M)	(310.0M)	(294.5M)
Accounts Payable	2.8M	1.6M	3.2M	3.0M	3.2M	2.7M
Cash	73.3M	361.4M	172.5M	108.3M	38.5M	36.6M
Non Current Assets Total	940K	770K	30.3M	23.3M	44.7M	47.0M
Cash And Short Term Investments	101.5M	361.4M	297.2M	241.1M	203.9M	232.3M
Common Stock Shares Outstanding	43.0M	44.8M	45.1M	45.6M	48.0M	47.3M
Short Term Investments	28.2M	0.0	124.7M	132.8M	165.4M	88.5M
Liabilities And Stockholders Equity	103.0M	365.5M	331.6M	270.3M	252.2M	254.1M
Non Current Liabilities Total	169.0M	1.6M	10.8M	13.4M	12.4M	11.8M
Other Current Assets	607K	3.3M	3.3M	5.1M	3.5M	3.0M
Other Stockholder Equity	4.8M	103.5M	476.4M	487.5M	535.5M	295.5M
Total Liab	173.5M	6.4M	23.0M	24.3M	26.5M	48.4M
Net Invested Capital	(70.5M)	359.1M	308.6M	246.0M	225.7M	187.5M
Property Plant And Equipment Gross	739K	569K	13.2M	20.5M	22.3M	23.4M
Total Current Assets	102.1M	364.8M	301.3M	247.0M	207.4M	235.5M
Net Working Capital	97.6M	358.4M	289.1M	236.2M	193.4M	226.3M
Property Plant Equipment	739K	569K	13.2M	11.0M	12.6M	13.2M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Pmv PharmaceuticalsInc is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Pmv Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Pmv Pharmaceuticalsinc Stock. Highlighted below are key reports to facilitate an investment decision about Pmv Pharmaceuticalsinc Stock:

How To Invest In Pmv

Details

Is Pmv Stock a good investment?

Details

What is Pmv PharmaceuticalsI's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pmv PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Pmv Stock analysis

When running Pmv PharmaceuticalsI's price analysis, check to measure Pmv PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pmv PharmaceuticalsI is operating at the current time. Most of Pmv PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Pmv PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pmv PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Pmv PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.

	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets

Is Pmv PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pmv PharmaceuticalsI. If investors know Pmv will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pmv PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.32)

Return On Assets

(0.19)

Return On Equity

(0.29)

The market value of Pmv PharmaceuticalsInc is measured differently than its book value, which is the value of Pmv that is recorded on the company's balance sheet. Investors also form their own opinion of Pmv PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Pmv PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pmv PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Pmv PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pmv PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pmv PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pmv PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pmv Capital Surpluse vs Accounts Payable Analysis

Capital Surpluse vs Accounts Payable

Capital Surpluse vs Accounts Payable Correlation Analysis

Correlation Coefficient

Capital Surpluse

Accounts Payable

Pmv PharmaceuticalsI fundamental ratios Correlations

Pmv PharmaceuticalsI Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pmv PharmaceuticalsI fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Pmv Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Net Tangible Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Net Working Capital	+ 1.0	Cash And Short Term Investments

Property Plant And Equipment Gross	- 0.98	Retained Earnings
Non Current Assets Total	- 0.96	Retained Earnings
Net Invested Capital	- 0.95	Total Liab
Net Invested Capital	- 0.95	Non Current Liabilities Total
Non Current Liabilities Other	- 0.95	Retained Earnings
Total Liab	- 0.95	Net Tangible Assets